We serve Chemical Name:2-oxo-2-(2-phenylindolizin-3-yl)acetic acid CAS:892691-05-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-oxo-2-(2-phenylindolizin-3-yl)acetic acid
CAS.NO:892691-05-3
Synonyms:3-Indolizineacetic acid,a-oxo-2-phenyl
Molecular Formula:C16H11NO3
Molecular Weight:265.26300
HS Code:2918300090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:1.27g/cm3
Index of Refraction:1.644
PSA:58.78000
Exact Mass:265.07400
LogP:2.87360
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 3-Indolizineacetic acid,a-oxo-2-phenyl chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-Indolizineacetic acid,a-oxo-2-phenyl physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Indolizineacetic acid,a-oxo-2-phenyl Use and application,3-Indolizineacetic acid,a-oxo-2-phenyl technical grade,usp/ep/jp grade.
Related News: As far as chemical raw materials are concerned, China occupies a large share in the field of bulk raw materials and has become one of the world’s largest suppliers of chemical raw materials. 2-oxo-2-(2-phenylindolizin-3-yl)acetic acid manufacturer We purchase the raw materials from raw material or chemical product manufacturers both in Japan and internationally. 2-oxo-2-(2-phenylindolizin-3-yl)acetic acid supplier That impacts airlines’ business, making it less financially attractive for them to fly those routes to China. 2-oxo-2-(2-phenylindolizin-3-yl)acetic acid vendor Catalent��s clinical supply network includes nine cGMP-certified clinical packaging facilities across North America, Europe and Asia, and more than 50 strategically-located depots around the world, providing local and regional options for clinical storage, distribution, expiry update and relabeling services, and clinical returns management. 2-oxo-2-(2-phenylindolizin-3-yl)acetic acid factory As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL.
